You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

ACCRUFER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Accrufer, and when can generic versions of Accrufer launch?

Accrufer is a drug marketed by Shield Tx and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-one patent family members in nineteen countries.

The generic ingredient in ACCRUFER is ferric maltol. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ferric maltol profile page.

DrugPatentWatch® Generic Entry Outlook for Accrufer

Accrufer was eligible for patent challenges on July 25, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 23, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try for Free

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ACCRUFER?
  • What are the global sales for ACCRUFER?
  • What is Average Wholesale Price for ACCRUFER?
Summary for ACCRUFER
International Patents:51
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 1
Drug Prices: Drug price information for ACCRUFER
What excipients (inactive ingredients) are in ACCRUFER?ACCRUFER excipients list
DailyMed Link:ACCRUFER at DailyMed
Drug patent expirations by year for ACCRUFER
Drug Prices for ACCRUFER

See drug prices for ACCRUFER

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ACCRUFER
Generic Entry Date for ACCRUFER*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ACCRUFER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Shield TherapeuticsPhase 1

See all ACCRUFER clinical trials

US Patents and Regulatory Information for ACCRUFER

ACCRUFER is protected by three US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ACCRUFER is ⤷  Try for Free.

This potential generic entry date is based on patent ⤷  Try for Free.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shield Tx ACCRUFER ferric maltol CAPSULE;ORAL 212320-001 Jul 25, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Shield Tx ACCRUFER ferric maltol CAPSULE;ORAL 212320-001 Jul 25, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Shield Tx ACCRUFER ferric maltol CAPSULE;ORAL 212320-001 Jul 25, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
Shield Tx ACCRUFER ferric maltol CAPSULE;ORAL 212320-001 Jul 25, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ACCRUFER

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Norgine B.V. Feraccru ferric maltol EMEA/H/C/002733
Feraccru is indicated in adults for the treatment of iron deficiency.
Authorised no no no 2016-02-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ACCRUFER

When does loss-of-exclusivity occur for ACCRUFER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 15340825
Patent: Crystalline forms of ferric maltol
Estimated Expiration: ⤷  Try for Free

Brazil

Patent: 2017008903
Patent: formas cristalinas de maltol férrico
Estimated Expiration: ⤷  Try for Free

Canada

Patent: 44210
Patent: FORMES CRISTALLINES DE MALTOL FERRIQUE (CRYSTALLINE FORMS)
Estimated Expiration: ⤷  Try for Free

Chile

Patent: 17001030
Patent: Formas cristalinas de maltol férrico
Estimated Expiration: ⤷  Try for Free

China

Patent: 7001310
Patent: 麦芽酚铁的结晶形式 (Crystalline forms of ferric maltol)
Estimated Expiration: ⤷  Try for Free

Eurasian Patent Organization

Patent: 3323
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ ЖЕЛЕЗНОЙ СОЛИ МАЛЬТОЛА (CRYSTALLINE FORMS OF FERRIC MALTOL)
Estimated Expiration: ⤷  Try for Free

Patent: 1790667
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ ЖЕЛЕЗНОЙ СОЛИ МАЛЬТОЛА
Estimated Expiration: ⤷  Try for Free

European Patent Office

Patent: 60951
Patent: FORMES CRISTALLINES DE MALTOL FERRIQUE (CRYSTALLINE FORMS OF FERRIC MALTOL)
Estimated Expiration: ⤷  Try for Free

Japan

Patent: 04358
Estimated Expiration: ⤷  Try for Free

Patent: 78711
Estimated Expiration: ⤷  Try for Free

Patent: 17535510
Patent: マルトール第二鉄の結晶形態
Estimated Expiration: ⤷  Try for Free

Patent: 18197268
Patent: マルトール第二鉄の結晶形態 (CRYSTAL FORM OF FERRIC MALTOL)
Estimated Expiration: ⤷  Try for Free

Mexico

Patent: 0730
Patent: FORMAS CRISTALINAS DE MALTOL FÉRRICO. (CRYSTALLINE FORMS OF FERRIC MALTOL.)
Estimated Expiration: ⤷  Try for Free

Patent: 17005413
Patent: FORMAS CRISTALINAS DE MALTOL FERRICO. (CRYSTALLINE FORMS OF FERRIC MALTOL.)
Estimated Expiration: ⤷  Try for Free

Poland

Patent: 60951
Estimated Expiration: ⤷  Try for Free

Saudi Arabia

Patent: 7381406
Patent: صور بلورية من مالتول الحديديك (Crystalline Forms of Ferric Maltol)
Estimated Expiration: ⤷  Try for Free

Singapore

Patent: 201702639R
Patent: CRYSTALLINE FORMS OF FERRIC MALTOL
Estimated Expiration: ⤷  Try for Free

South Africa

Patent: 1702136
Patent: CRYSTALLINE FORMS OF FERRIC MALTOL
Estimated Expiration: ⤷  Try for Free

South Korea

Patent: 2576930
Estimated Expiration: ⤷  Try for Free

Patent: 170071446
Patent: 제2철 말톨의 결정질 형태 (2 CRYSTALLINE FORMS OF FERRIC MALTOL)
Estimated Expiration: ⤷  Try for Free

Spain

Patent: 61944
Estimated Expiration: ⤷  Try for Free

United Kingdom

Patent: 31742
Patent: Crystalline forms
Estimated Expiration: ⤷  Try for Free

Patent: 1419174
Estimated Expiration: ⤷  Try for Free

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ACCRUFER around the world.

Country Patent Number Title Estimated Expiration
Spain 2785391 ⤷  Try for Free
Japan 6404358 ⤷  Try for Free
South Korea 102351422 ⤷  Try for Free
Japan 2017501235 ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory for Accrufer

Introduction to Accrufer

Accrufer, also known as Feraccru, is a proprietary FDA-approved oral iron treatment developed by Shield Therapeutics. It is designed to address iron deficiency and iron deficiency anemia (IDA) with a broad label, making it a highly tolerable and effective solution compared to conventional iron treatments[2][3][4].

Market Opportunity and Growth Potential

Addressing Unmet Needs

Accrufer fills a significant unmet need in the iron deficiency market, particularly in the US where approximately 20 million individuals suffer from iron deficiency with or without anemia. This large and defined market presents a ripe opportunity for disruption and growth[2][3].

Regulatory Approvals and Expansion

Shield Therapeutics has made significant strides in expanding Accrufer's reach. The drug has been approved in the US since 2019, and the company is awaiting regulatory approval in Canada, expected in the first half of 2024. Additionally, a New Drug Application (NDA) is in progress in Korea[2][4].

Financial Performance and Revenue Growth

FY23 Financial Highlights

In the fiscal year 2023, Shield Therapeutics reported substantial growth in revenues and prescriptions for Accrufer. Total revenues and other income increased to $17.5 million, a 2.8x increase from FY22. Accrufer revenue specifically jumped to $11.6 million, a 3.1x increase from the previous year. Ex-US revenue was $1.5 million, and other income, including Viatris milestone payments, was $4.4 million[1][2].

Prescription Growth

The number of Accrufer prescriptions in FY23 was 77,000, adjusted from an initial figure of 90,500 due to a third-party data error. This still represents a 3.1x increase over FY22. The average net selling price per prescription in H2 2023 was $145, a 21% increase from H1 2023[1][2].

Strategic Partnerships and Sales Force Expansion

Viatris Partnership

A key factor in Accrufer's success is the collaborative sales agreement with Viatris Inc., formed in May 2023. This partnership has enabled Shield Therapeutics to target over 12,000 high-prescribing healthcare professionals in the US, significantly boosting prescription growth and revenue[1][4].

Sales Force Expansion

Shield Therapeutics has expanded its US sales force to 100 dedicated sales representatives, focusing on the highest prescribers of oral iron treatments. This strategic move has been instrumental in driving the growth of Accrufer prescriptions and revenues[3][4].

Cash Flow Management and Capital Structure

Cash Position and Financing

As of December 31, 2023, Shield Therapeutics had a cash balance of $13.9 million. The company has secured additional financing, including a $20 million term loan and equity financing of up to $7.4 million, to support its growth plans and aim for cash flow break-even by the end of 2024[1][5].

Cost Management and Efficiency

Shield Therapeutics is implementing measures to manage its cash flow effectively, including reductions in operating expenses and enhancements in working capital. These efforts are aimed at achieving cash flow positivity by H2 2025[1][5].

Key Performance Indicators (KPIs) and Growth Metrics

Revenue and Prescription Metrics

The company tracks key financial metrics such as US Accrufer revenue, net sales per prescription, and the number of prescriptions. These KPIs indicate strong growth, with Accrufer revenue and prescriptions tripling in FY23 compared to FY22[2][5].

Gross-to-Net Improvement

There was a notable improvement in the gross-to-net margin for Accrufer in FY23, with a 21% increase in the average net selling price per prescription in H2 2023 compared to H1 2023. This trend is expected to continue into FY24[1][2].

Future Outlook and Market Adoption

Expansion Plans

Shield Therapeutics is set to continue its aggressive expansion plans, including further penetration into the US market and expansion into new markets such as Canada and Korea. The company is also conducting studies to evaluate Accrufer's efficacy in children, which could open up additional market segments[3][4].

Regulatory and Clinical Milestones

The company is awaiting regulatory approval in Canada and expects to complete enrollment for a pediatric study in H1 2024, with results anticipated in H2 2024. These milestones are crucial for further market adoption and revenue growth[3][4].

Industry and Market Validation

Expert Opinions and Market Research

Recent market research has reaffirmed the unmet need in the target patient population for a well-tolerated and effective oral iron treatment. Healthcare professionals and patients continue to seek alternatives to conventional iron treatments, validating Accrufer's market position[1][2].

Competitive Advantage

Accrufer's broad FDA approval and its low side effect profile make it a potential best-in-class solution in the oral iron market. This competitive advantage, combined with the strong sales and marketing efforts, positions Accrufer for continued market dominance[2][3].

Challenges and Adjustments

Data Adjustments and Financial Reporting

Shield Therapeutics adjusted its total prescriptions figure for FY23 due to an error by a third-party data provider. However, this adjustment did not affect the financials, including revenues and compliance with financial covenants[1].

Key Takeaways

  • Substantial Revenue Growth: Accrufer revenue tripled in FY23, reaching $11.6 million.
  • Prescription Growth: Accrufer prescriptions increased by 3.1x in FY23, totaling 77,000.
  • Strategic Partnerships: The partnership with Viatris has been instrumental in driving growth.
  • Cash Flow Management: Shield Therapeutics is on track to achieve cash flow break-even by the end of 2024.
  • Market Expansion: The company is expanding into new markets and conducting clinical studies to further validate Accrufer.

Frequently Asked Questions (FAQs)

1. What is Accrufer, and how does it differ from conventional iron treatments?

Accrufer is an FDA-approved oral iron treatment for iron deficiency and IDA, known for its high tolerability and low side effect profile, making it a preferred alternative to conventional iron treatments.

2. How has the partnership with Viatris impacted Accrufer's sales?

The partnership with Viatris has significantly boosted Accrufer's prescription growth and revenue by targeting over 12,000 high-prescribing healthcare professionals in the US.

3. What are the key financial metrics indicating Accrufer's growth?

Key metrics include a 3.1x increase in Accrufer revenue and prescriptions in FY23, a 21% increase in the average net selling price per prescription, and a strong cash balance to support future growth.

4. What are Shield Therapeutics' plans for expanding Accrufer's market reach?

Shield Therapeutics plans to expand into Canada and Korea, conduct pediatric studies, and further penetrate the US market to increase market adoption and revenue.

5. When does Shield Therapeutics expect to achieve cash flow break-even?

Shield Therapeutics aims to achieve cash flow break-even by the end of 2024, supported by its current financing and cost management strategies.

Cited Sources:

  1. Vox Markets: Shield Therapeutics triples Accrufer revenues and prescriptions in FY23.
  2. Shield Therapeutics: Financial statements for the year ended December 31, 2023.
  3. Annual Reports: Shield Therapeutics plc Annual report and accounts 2022.
  4. Marketscreener: Shield Therapeutics 2022 revenue jumps on Accrufer iron tablet sales.
  5. Investegate: Interim results update and business update by Shield Therapeutics.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.